Additionally, a recent abstract suggests that in glioma cell lines engineered to express the KIAA1549:BRAF fusion, there is resistance to therapy with BRAF V600E inhibitors, and in fact, the paradoxical growth activation (previously only seen in wild-type BRAF cells treated with BRAF V600E inhibitors) is observed (Lang et al., 2012). This evidence concerns the gene BRAF and glioma.